Old API Wind-Down logo

ARLZQ - Old API Wind-Down News Story

$0.003 0.0  0.0%

Last Trade - 17/05/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £89.8m
Position in Universe th / 6358

BRIEF-Intercept Announces NASH And PBC Program Updates

Mon 7th January, 2019 12:13pm
Jan 7 (Reuters) - Intercept Pharmaceuticals Inc  ICPT.O :
    * INTERCEPT ANNOUNCES NASH AND PBC PROGRAM UPDATES
    * INTERCEPT PHARMACEUTICALS INC - PHASE 3 REVERSE TRIAL OF
OCA IN
NASH PATIENTS WITH COMPENSATED CIRRHOSIS PROJECTED TO COMPLETE
ENROLLMENT IN 2019
    * INTERCEPT PHARMACEUTICALS INC - INTERCEPT ACQUIRES LICENSE
TO
U.S. DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO PAN-PPAR
AGONIST BEZAFIBRATE
    * INTERCEPT- DATA FROM INTERIM ANALYSIS OF PHASE 3
REGENERATE
TRIAL OF OBETICHOLIC ACID IN NASH PATIENTS WITH ADVANCED
FIBROSIS ANTICIPATED IN Q1 2019
    * INTERCEPT PHARMACEUTICALS INC - HAS ACQUIRED FROM ARALEZ
PHARMACEUTICALS INC. ITS LICENSE TO DEVELOP AND COMMERCIALIZE
BEZAFIBRATE IN U.S.

Source text for Eikon:  ID:nGNX6PqwkD 
Further company coverage:  ICPT.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.